Bortez1 mg/vial

Bortez is a proteasome inhibitor chemotherapy agent used in the treatment of certain blood cancers. Its evidence-based indications are:

FDA-approved / Established indications

• Multiple myeloma — Bortez is approved for the treatment of adult patients with multiple myeloma, including previously untreated disease (in combination with melphalan and prednisone) and relapsed/refractory disease (as a single agent or in combination regimens).
• Mantle cell lymphoma — Bortez is approved for the treatment of adult patients with mantle cell lymphoma, including previously untreated disease (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone) and relapsed/refractory disease.

Combination therapy requirement

For previously untreated multiple myeloma and previously untreated mantle cell lymphoma, Bortez must be used as part of a combination chemotherapy regimen rather than alone; see Dosage and Administration for regimen details.

Bortez is used only under the supervision of a physician experienced in the use of cancer chemotherapy.

Each vial contains Bortezomib as the active ingredient, supplied as a sterile lyophilized (freeze-dried) powder for reconstitution, typically available in strengths of 1 mg and 3.5 mg per vial. Mannitol is included as a bulking agent/stabilizer in the formulation.

Bortez is a small-molecule, boron-containing dipeptide that selectively and reversibly inhibits the 26S proteasome, a key enzyme complex responsible for degrading regulatory proteins inside cells. It belongs to the proteasome inhibitor class of antineoplastic (anticancer) agents and is administered as an intravenous or subcutaneous injection in a hospital or specialized oncology care setting, never orally and never intrathecally.

Bortez belongs to the therapeutic class of Antineoplastic agents — Proteasome inhibitors, a class of targeted chemotherapy drugs used in the treatment of hematologic malignancies.

Mechanism

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The ubiquitin-proteasome pathway normally degrades intracellular proteins that regulate cell cycle progression and apoptosis. By inhibiting this pathway, Bortezomib disrupts normal cellular homeostatic mechanisms, leading to cell cycle arrest and apoptosis of malignant plasma cells and lymphoma cells, which appear to be particularly sensitive to proteasome inhibition.

Pharmacokinetics

After intravenous or subcutaneous administration, Bortezomib is widely distributed to peripheral tissues. It is metabolized in the liver primarily via oxidative deamination by cytochrome P450 enzymes, chiefly CYP3A4 and CYP2C19, with minor contributions from other CYP isoenzymes. The mean elimination half-life after multiple dosing ranges from approximately 40 to 193 hours depending on the dose and route.

Bortez is given by intravenous (IV) bolus injection over 3-5 seconds or by subcutaneous (SC) injection, depending on the specific product formulation and physician's choice; subcutaneous administration is generally preferred where available because it is associated with a lower incidence of severe peripheral neuropathy. At least 72 hours should separate consecutive doses.

Bortez must NEVER be given by the intrathecal route — intrathecal administration has resulted in fatal outcomes. It must be administered only by, or under the direct supervision of, a physician experienced in the use of cancer chemotherapeutic agents.

CYP3A4 inhibitors

Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase exposure to Bortez; concomitant use should be closely monitored and a dose reduction of Bortez considered.

CYP3A4 inducers

Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can substantially decrease Bortez exposure and efficacy; concomitant use should generally be avoided.

Oral antidiabetic agents

Hypoglycemia and hyperglycemia have been reported in diabetic patients receiving oral antidiabetic agents together with Bortez; blood glucose should be monitored closely and antidiabetic medication doses adjusted as needed.

Other cytotoxic/neurotoxic agents

Concurrent use with other agents that cause peripheral neuropathy or hypotension may increase the risk and severity of these effects with Bortez; see Precautions and Warnings.

Adverse effects associated with Bortez range from very common to rare but serious:

Very common

• Peripheral neuropathy (sensory, sometimes painful; can be dose-limiting and may be irreversible in some patients)
• Thrombocytopenia and other cytopenias (anemia, neutropenia)
• Nausea, vomiting, diarrhea, constipation, decreased appetite
• Fatigue, asthenia, fever

Common

• Hypotension, including orthostatic (postural) hypotension
• Herpes zoster reactivation
• Rash and other skin reactions

Rare but serious

• Acute diffuse infiltrative pulmonary disease and other pulmonary toxicity
• Posterior reversible encephalopathy syndrome (PRES)
• Tumor lysis syndrome, particularly in patients with high tumor burden
• Acute liver failure/hepatotoxicity
• Cardiac disorders, including heart failure

Patients should promptly report new neurological symptoms, unusual bleeding or bruising, dizziness/fainting, shortness of breath, or signs of infection to their physician.

Pregnancy: Bortez can cause fetal harm based on its mechanism of action and animal reproduction studies showing post-implantation loss at doses below the recommended human dose. Bortez should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; women of reproductive potential should use effective contraception during treatment and for at least 7 months after the final dose, and males with female partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the final dose. Always consult a physician before use in pregnancy.

Lactation: It is not known whether Bortez passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed infant, women should be advised not to breastfeed during treatment with Bortez and for at least 2 months after the final dose.

Bortez carries several important safety warnings requiring close monitoring by an experienced oncology team:

• Peripheral neuropathy: Common, may be severe and dose-limiting, and may be irreversible in some patients; assess neurological symptoms before each dose.
• Thrombocytopenia: Platelet counts should be monitored frequently throughout treatment; dose modification may be required for severe thrombocytopenia.
• Hypotension: Including orthostatic hypotension; use caution in patients with a history of syncope, dehydration, or on antihypertensive medications.
• Pulmonary toxicity: Rare but potentially fatal acute diffuse infiltrative pulmonary disease has been reported; interrupt therapy promptly for new or worsening pulmonary symptoms.
• Posterior reversible encephalopathy syndrome (PRES): Rare; consider brain imaging in patients presenting with seizures, hypertension, headache, altered consciousness, or visual disturbance, and discontinue Bortez if confirmed.
• Tumor lysis syndrome: Risk is greatest in patients with high tumor burden prior to treatment; monitor electrolytes and renal function closely.
• Herpes zoster reactivation: Antiviral prophylaxis is often recommended during treatment.
• Hepatotoxicity: Monitor liver function; rare cases of acute liver failure have been reported.
• Route of administration: Bortez must be given only by the intravenous or subcutaneous route, and must never be given intrathecally (see Contraindications) — this is a critical, potentially fatal medication-safety issue.

Bortez must be administered only under the supervision of a physician experienced in cancer chemotherapy, with regular clinical and laboratory monitoring throughout treatment.

There is no known specific antidote for Bortez overdose. Doses exceeding twice the recommended dose have been associated with fatal outcomes, including acute onset of symptomatic hypotension and severe thrombocytopenia. In case of suspected overdose, seek immediate medical attention or contact emergency services / a poison control center; management consists of monitoring vital signs and blood counts and providing appropriate supportive care (e.g., fluids, blood pressure support, platelet transfusion as needed) under hospital care.

Store unopened vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton, protected from light. Unopened vials may alternatively be stored at controlled room temperature (up to 25°C/77°F) for a limited period (up to 7 days) if refrigeration is not available — follow the product-specific label. Once reconstituted, use within 8 hours; reconstituted solution stored in the original vial or a syringe may be kept at room temperature under normal indoor lighting for up to 8 hours. Keep out of reach of children.

Pediatric patients

The safety and effectiveness of Bortez have not been established in pediatric patients. Limited experience in pediatric lymphoid malignancies has not shown clear benefit.

Elderly patients

No overall differences in effectiveness were observed between elderly and younger patients; however, elderly patients (particularly those over 75 years) may be more susceptible to certain adverse effects such as hypotension, fatigue, and gastrointestinal toxicity, warranting closer monitoring.

Renal impairment

No initial dose adjustment is required; patients on hemodialysis should receive Bortez after the dialysis session (see Dosage and Administration).

Hepatic impairment

Dose reduction is recommended for patients with moderate to severe hepatic impairment (see Dosage and Administration).

Duration of treatment with Bortez depends on the indication and regimen: previously untreated multiple myeloma combination therapy is typically given for approximately 9 cycles (about 54 weeks), previously untreated mantle cell lymphoma combination therapy for up to 6 cycles, and relapsed/refractory disease regimens are generally continued for as long as the patient shows clinical benefit and tolerates therapy, subject to reassessment by the treating oncologist and dose interruption or discontinuation for significant toxicity.

For intravenous use: Reconstitute the 3.5 mg vial of Bortez with 3.5 mL of 0.9% Sodium Chloride Injection, USP, to yield a final concentration of 1 mg/mL. Administer as a 3-5 second IV bolus injection.

For subcutaneous use (where the specific product formulation supports this route): Reconstitute the 3.5 mg vial with 1.4 mL of 0.9% Sodium Chloride Injection, USP, to yield a final concentration of 2.5 mg/mL; inject subcutaneously into the thigh or abdomen, rotating injection sites.

Reconstituted solution is clear and colorless, should be inspected visually for particulate matter and discoloration prior to use, and must be used within 8 hours of preparation. Bortez for injection is a lyophilized powder and must always be reconstituted only with 0.9% Sodium Chloride Injection, USP, prior to administration — never administer intrathecally.

Bortezomib belongs to the drug class of Antineoplastic agents, Proteasome inhibitors (a subclass of targeted chemotherapy agents used in hematologic malignancies).

Bortezomib is a reversible inhibitor of the 26S proteasome's chymotrypsin-like activity. By blocking targeted proteolysis, Bortezomib disrupts multiple intracellular signaling cascades that malignant plasma cells and lymphoma cells depend on for survival, including pathways regulating NF-κB activity and cell-cycle checkpoint proteins. This disruption leads to accumulation of pro-apoptotic proteins, cell cycle arrest, and programmed cell death (apoptosis) preferentially in cancer cells, which are especially reliant on high proteasomal turnover.

D

The safety and effectiveness of Bortez have not been established in pediatric patients. Limited clinical experience in children and adolescents with lymphoid malignancies has been reported but has not demonstrated a clear treatment benefit, and Bortez is not recommended for routine use in this population outside of a clinical trial setting.